Different contributions of endothelin-A and endothelin-B receptors in the pathogenesis of deoxycorticosterone acetate-salt-induced hypertension in rats

被引:102
作者
Matsumura, Y
Hashimoto, N
Taira, S
Kuro, T
Kitano, R
Ohkita, M
Opgenorth, TJ
Takaoka, M
机构
[1] Osaka Univ Pharmaceut Sci, Dept Pharmacol, Osaka 5691094, Japan
[2] Abbott Labs, Diabet & Vasc Res Div, Abbott Pk, IL 60064 USA
关键词
receptors; endothelin; hypertension; DOCA-salt; renal function; vascular hypertrophy;
D O I
10.1161/01.HYP.33.2.759
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
We investigated the involvement of actions mediated by endothelin-A (ETA) and endothelin-A (ETB) receptors in the pathogenesis of deoxycorticosterone acetate (DOCA)-salt-induced hypertension in rats. Two weeks after the start of DOCA-salt treatment, rats were given ABT-627 (10 [mg/kg]/d), a selective ETA receptor antagonist; A-192621 (30 [mg/kg]/d), a selective ETB receptor antagonist; or their vehicle for 2 weeks. Uninephrectomized rats without DOCA-salt treatment served as controls. Treatment with DOCA and salt for 2 weeks led to a mild but significant hypertension; in vehicle-treated DOCA-saIt rats, systolic blood pressure increased markedly after 3 to 4 weeks. Daily administration of ABT-627 for 2 weeks almost abolished any further increases in blood pressure, whereas A-192621 did not affect the development of DOCA-salt-induced hypertension. When the degree of vascular hypertrophy of the aorta was histochemically evaluated at 4 weeks, there were significant increases in wall thickness, wall area, and wall-to-lumen ratio in vehicle-treated DOCA-salt rats compared with uninephrectomized control rats. The development of vascular hypertrophy was markedly suppressed by ABT-627. In contrast, treatment with A-192621 significantly exaggerated these vascular changes. In vehicle-treated DOCA-salt rats, renal blood flow and creatinine clearance decreased, and urinary excretion of protein, blood urea nitrogen, fractional excretion of sodium, and urinary N-acetyl-beta-glucosaminidase activity increased. Such damage was overcome by treatment with ABT-627 but not with A-192621; indeed, the latter agent led to worsening of the renal dysfunction. Histopathologic examination of the kidney in vehicle-treated DOCA-salt rats revealed tubular dilatation and atrophy as well as thickening of small arteries. Such damage was reduced in animals given ABT-627, whereas more severe histopathologic changes were observed in A-192621-treated animals. These results strongly support the view that ETA receptor-mediated action plays an important role in the pathogenesis of DOCA-salt-induced hypertension. On the other hand, it seems likely that the ETB receptor-mediated action protects against vascular and renal injuries in this model of hypertension. A selective ETA receptor antagonist is likely to be useful for treatment of subjects with mineralocorticoid-dependent hypertension; whereas ETB-selective antagonism alone is detrimental to such cases.
引用
收藏
页码:759 / 765
页数:7
相关论文
共 32 条
[1]   ETA receptor blockade attenuates the hypertension but not renal dysfunction in DOCA-salt rats [J].
Allcock, GH ;
Venema, RC ;
Pollock, DM .
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 1998, 275 (01) :R245-R252
[2]   A SPECIFIC ENDOTHELIN SUBTYPE-A RECEPTOR ANTAGONIST PROTECTS AGAINST INJURY IN RENAL-DISEASE PROGRESSION [J].
BENIGNI, A ;
ZOJA, C ;
CORNA, D ;
ORISIO, S ;
LONGARETTI, L ;
BERTANI, T ;
REMUZZI, G .
KIDNEY INTERNATIONAL, 1993, 44 (02) :440-444
[3]   Selective antagonism of the ETA receptor reduces neointimal hyperplasia after balloon-induced vascular injury in pigs [J].
Burke, SE ;
Lubbers, NL ;
Gagne, GD ;
Wessale, JL ;
Dayton, BD ;
Wegner, CD ;
Opgenorth, TJ .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1997, 30 (01) :33-41
[4]   EFFECT OF AN ENDOTHELIN-RECEPTOR ANTAGONIST ON ISCHEMIC ACUTE-RENAL-FAILURE [J].
CHAN, L ;
CHITTINANDANA, A ;
SHAPIRO, JI ;
SHANLEY, PF ;
SCHRIER, RW .
AMERICAN JOURNAL OF PHYSIOLOGY, 1994, 266 (01) :F135-F138
[5]   The orally active nonpeptide endothelin A-receptor antagonist A-127722 prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling in Sprague-Dawley rats [J].
Chen, SJ ;
Chen, YF ;
Opgenorth, TJ ;
Wessale, JL ;
Meng, QC ;
Durand, J ;
DiCarlo, VS ;
Oparil, S .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1997, 29 (06) :713-725
[6]   The role of ET(B) receptors in normotensive and hypertensive rats as revealed by the non-peptide selective ET(B) receptor antagonist Ro 46-8443 [J].
Clozel, M ;
Breu, V .
FEBS LETTERS, 1996, 383 (1-2) :42-45
[7]   ORGAN DISTRIBUTION OF THE 3 RAT ENDOTHELIN MESSENGER-RNAS AND THE EFFECTS OF ISCHEMIA ON RENAL GENE-EXPRESSION [J].
FIRTH, JD ;
RATCLIFFE, PJ .
JOURNAL OF CLINICAL INVESTIGATION, 1992, 90 (03) :1023-1031
[8]   Effects of the endothelin ET(A)-receptor antagonist FR139317 on development of hypertension and cardiovascular hypertrophy in deoxycorticosterone acetate-salt hypertensive rats [J].
Fujita, K ;
Matsumura, Y ;
Miyazaki, Y ;
Takaoka, M ;
Morimoto, S .
JAPANESE JOURNAL OF PHARMACOLOGY, 1996, 70 (04) :313-319
[9]   ROLE OF ENDOTHELIN-1 AND THE ET(A) RECEPTOR IN THE MAINTENANCE OF DEOXYCORTICOSTERONE ACETATE-SALT-INDUCED HYPERTENSION [J].
FUJITA, K ;
MATSUMURA, Y ;
KITA, S ;
MIYAZAKI, Y ;
HISAKI, K ;
TAKAOKA, M ;
MORIMOTO, S .
BRITISH JOURNAL OF PHARMACOLOGY, 1995, 114 (05) :925-930
[10]  
Fujita Katsuya, 1996, Life Sciences, V58, pPL1